A trial to evaluate the efficacy and safety of Telomelysin in combination with immune check-point inhibitors

Trial Profile

A trial to evaluate the efficacy and safety of Telomelysin in combination with immune check-point inhibitors

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Telomelysin (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2016 New trial record
    • 31 Aug 2016 According to an Oncolys BioPharma media release, the company plans to conduct this trial in the US, based on the results of a phase II trial of telomelysin in patients with unresectable or metastatic melanoma (see CTP 700276918).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top